MAP2K7 and melanoma: These data are in agreement with results on the effect of this inhibitor class in the drug-resistant melanoma cell line SkMel-133, which also strongly impaired cell growth in response to the bromodomain inhibitor JQ1 in combination with MEK and ERK inhibitors in our earlier work [4].